Clinical trials: Alopecia
Alopecia Areata
Study To Evaluate The Efficacy Of Tofacitinib In Moderate To Severe Alopecia Areata, Totalis And Universalis
This is an open-label pilot study of tofacitinib taken daily for 6 months in the treatment of moderate to severe AA, and alopecia totalis or universalis, followed by 6 months follow-up off drug to assess the incidence and timing…
- Trial name
- NCT02299297
- Testing
- Tofacitinib
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Columbia University
Alopecia
ATI-501 Oral Suspension Compared to Placebo in Subjects With Alopecia Areata, Alopecia Universalis or Alopecia Totalis
This Phase 2, multicenter, randomized study will evaluate the safety, tolerability and efficacy of ATI-501 for the treatment of Alopecia Areata (AA), Alopecia Universalis (AU) or Alopecia Totalis (AT) in adult subjects.
- Trial name
- NCT03594227
- Testing
- ATI-501 400mg BID (Low dose), ATI-501 600mg BID (Mid dose), ATI-501 800mg BID (High dose)
- Where
- 25 sites in United States
- Volunteers
- 87 people, healthy volunteers welcome
- Sponsor
- Aclaris Therapeutics, Inc.
Keratosis, Actinic
A Study to Evaluate the Safety and Tolerability of Tirbanibulin Ointment 1% in Adult Participants With Actinic Keratosis
The purpose of the study is to evaluate the safety, tolerability and treatment effect of tirbanibulin ointment 1% when applied to a field of approximately 100 cm^2 on the face or balding scalp.
- Trial name
- NCT05279131
- Testing
- Tirbanibulin ointment 1%
- Where
- 7 sites in United States
- Volunteers
- 105 people
- Sponsor
- Almirall, S.A.
Alopecia Areata
Safety and Efficacy of Oral Etrasimod in Adult Participants With Moderate-to-Severe Alopecia Areata
The purpose of this study is to evaluate the safety and efficacy of etrasimod monotherapy (2 milligrams [mg] and 3 mg) in participants with moderate-to-severe alopecia areata (AA).
- Trial name
- NCT04556734
- Testing
- Etrasimod
- Where
- 42 sites in United States, Canada
- Volunteers
- 80 people
- Sponsor
- Pfizer
Central Centrifugal Cicatricial Alopecia
A Study of Revian Red All LED Cap as a Novel Treatment for Central Centrifugal Cicatricial Alopecia
The purpose of this study is to determine if the Revian Red All LED cap shows potential to be an effective treatment for Central centrifugal cicatricial alopecia (CCCA) by recruiting hair follicles back to anagen growth or by…
- Trial name
- NCT05759338
- Testing
- Revian Red All LED cap
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Wake Forest University Health Sciences
Alopecia
Platelet Rich Plasma Versus Minoxidil Foam for Treatment of Androgenic Alopecia in Women
The primary objective of this proposal is to conduct a study that assesses the safety, feasibility and efficacy of using PRP to treat this type of hair loss.
- Trial name
- NCT03488108
- Testing
- Platelet Rich Plasma, Minoxidil Foam
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Polycystic Ovary Syndrome (PCOS)
MLE4901 vs. Placebo for the Treatment of PCOS
This is a Phase 2b double-blind, randomized, parallel-group, placebo-controlled study of MLE4901 versus placebo in women with PCOS.
- Trial name
- NCT02865915
- Testing
- MLE4901
- Where
- 31 sites in United States
- Volunteers
- 55 people
- Sponsor
- Millendo Therapeutics US, Inc.
Alopecia Areata
Healthcare Disparities in Alopecia Areata
Alopecia areata (AA) is a common immune-mediated non-scarring alopecia often associated with substantial morbidity. There are however, limited population-based data on potential disparities in the burden of AA, including across…
- Trial name
- NCT05727306
- Testing
- No intervention
- Where
- United Kingdom
- Volunteers
- 4,052,231 people
- Sponsor
- Momentum Data
Androgenetic Alopecia, Hair Loss
Treatment of Androgenetic Alopecia in Females, 9 Beam
The purpose of this study is to evaluate the efficacy of the HairMax LaserComb 2009 9 beam model in promoting hair growth in females diagnosed with androgenetic alopecia when treatment is applied as directed.
- Conditions
- Androgenetic Alopecia, Hair Loss, Female Pattern Baldness
- Trial name
- NCT00981461
- Testing
- HairMax LaserComb, Control Device
- Where
- 5 sites in United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Lexington International, LLC
Androgenetic Alopecia
A Novel Approach to Treating Androgenetic Alopecia in Females With Low Level Laser Therapy
This study will acquire data on hair growth of the head that is the result of treatment with a non-heat generating, laser product.
- Trial name
- NCT01967277
- Testing
- Handi-Dome Laser, Incandescent red light source.
- Where
- 2 sites in United States
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Capillus, LLC
Actinic Keratosis
Study Comparing Imiquimod Cream, 3.75% to Zyclara® (Imiquimod) Cream, 3.75% in the Treatment of Actinic Keratosis
To determine the comparability of the safety and efficacy of Imiquimod Cream, 3.75% and Zyclara (imiquimod) Cream, 3.75% (the reference listed drug) in subjects with actinic keratosis (AK) of the face or balding scalp.
- Trial name
- NCT01686152
- Testing
- Imiquimod Cream, 3.75%, Zyclara®, Vehicle of Test Product
- Where
- 23 sites in United States
- Volunteers
- 589 people
- Sponsor
- Teva Pharmaceuticals USA
Alopecia
A Safety and Efficacy Study of Setipiprant Tablets in Androgenetic Alopecia in Males
This study will evaluate the safety, tolerability and efficacy of the oral administration of setipiprant tablets 1000 mg twice daily (BID) relative to placebo in 18 to 49 years old males with androgenetic alopecia (AGA).
- Trial name
- NCT02781311
- Testing
- Setipiprant, Finasteride
- Where
- 18 sites in United States
- Volunteers
- 169 people
- Sponsor
- Allergan
Alopecia Areata
A Study of ATI-50002 Topical Solution for the Treatment of Alopecia Areata
Primary: To assess safety, tolerability and efficacy of 2 dose strengths of ATI-50002 Topical Solution, compared to vehicle in subjects with alopecia areata (AA) Secondary: To evaluate key clinical outcome assessments
- Trial name
- NCT03354637
- Testing
- ATI-50002 high dose, ATI-50002 low dose
- Where
- 23 sites in United States
- Volunteers
- 129 people
- Sponsor
- Aclaris Therapeutics, Inc.
Androgenetic Alopecia
Modulated Light Therapy in Participants With Pattern Hair Loss
The REVIAN study is designed as a prospective, randomized, controlled, double-blind, parallel study to evaluate the efficacy and safety of the REVIAN System in male participants with androgenic alopecia.
- Trial name
- REV-01 (NCT04019795)
- Testing
- REVIAN 101, REVIAN 102, REVIAN 103
- Where
- 4 sites in Australia
- Volunteers
- 160 people
- Sponsor
- PhotonMD, Inc
Androgenic Alopecia
To Investigate Efficacy of FOL-005 on Hair Growth on Scalp Skin
The trial was a multicentre, randomised, double-blind, placebo controlled phase 2 trial. 60 healthy bald male subjects diagnosed with alopecia, who are between 18 and 55 years old and provide written informed consent were…
- Trial name
- NCT03467412
- Testing
- FOL-005
- Where
- 2 sites in Germany
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Follicum AB
Androgenic Alopecia
Follicular Revival in Androgenic Alopecia: Evaluating Use of Micro-needling
The intent of this study is to evaluate the efficacy of microneedling through use of a professional tattoo machine in hair regrowth in patients with androgenic alopecia (AGA) over up to 6 treatments (6 months).
- Trial name
- NCT04341363
- Testing
- Tattoo machine
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Yale University
Female Pattern Hair Loss, Androgenic Alopecia
Minoxidil 2% Solution and Botanical Hair Regimen in Women With Thinning Hair and Female Pattern Hair Loss/Androgenic Alopecia
The purpose of this study is to characterize the effect of Minoxidil 2% Solution and Botanical Hair Solution Regimen in women with thinning hair and female pattern hair loss/androgenic alopecia (Ludwig I and II).
- Trial name
- NCT02460497
- Testing
- Treatment: Minoxidil 2% / Botanical Hair Solution for Women
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- Galderma R&D
Frontal Fibrosing Alopecia, Lichen Planopilaris of Scalp
Effectiveness and Safety of Tofacitinib in Patients With Recalcitrant Frontal Fibrosing Alopecia : A Pilot Study
This study aims to determine the efficacy and safety of tofacitinib therapy in Thai patients with recalcitrant frontal fibrosing alopecia. The main questions are 1.
- Trial name
- Tofacitinib (NCT06202560)
- Testing
- Tofacitinib 5 MG
- Where
- Thailand
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- Institute of Dermatology, Thailand
Alopecia
Clinical Trial in Females With Female Pattern Hair Loss
This is a year-long clinical trial to evaluate the effectiveness and safety in women with Female Pattern Hair Loss (FPHL), comparing a new 5% minoxidil topical foam (MTF) formulation applied once a day versus the 2% minoxidil…
- Trial name
- NCT01145625
- Testing
- 5% Minoxidil, 2% Minoxidil
- Where
- 12 sites in United States, Canada and 3 more
- Volunteers
- 322 people
- Sponsor
- Johnson & Johnson Healthcare Products Division of McNEIL-PPC, Inc.
Alopecia Areata
A Study to Evaluate Efficacy and Safety of Deucravacitinib in Participants With Alopecia Areata
The purpose of this study is to evaluate the efficacy of deucravacitinib versus placebo at Week 24 and safety and tolerability of deucravacitinib versus placebo in adults with alopecia areata.
- Trial name
- NCT05556265
- Testing
- Deucravacitinib
- Where
- 28 sites in United States, Australia and 4 more
- Volunteers
- 94 people
- Sponsor
- Bristol-Myers Squibb